ARTHUR A. LEVIN - 17 Jun 2021 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Scientific Officer
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
17 Jun 2021
Net transactions value
-$5,302
Form type
4
Filing time
22 Jun 2021, 20:24:58 UTC
Previous filing
16 Jun 2021
Next filing
28 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $248 +200 +15% $1.24* 1,530 17 Jun 2021 Direct F1
transaction RNA Common Stock Sale $5,550 -200 -13% $27.75 1,330 17 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -200 -0.1% $0.000000 208,283 17 Jun 2021 Common Stock 200 $1.24 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.